A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
Phase 3 – large-scale trial before approval
Conditions:
Schizophrenia
Sponsor: Bristol-Myers Squibb Services Unlimited Company
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline in Clinical Global Impression -Severity (CGI-S) score at Week 5
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at Week 5
Description
Change from baseline in Clinical Global Impression -Severity (CGI-S) score at Week 5
Who can participate
Age group: 0-17 years
Gender: Female, Male
Target enrollment: 28 participants
БГ